PT  - JOURNAL ARTICLE
AU  - T Konishi
AU  - Y Yoshiyama
AU  - M Takamori
AU  - T Saida
TI  - Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)
AID  - 10.1136/jnnp.2004.042176
DP  - 2005 Mar 01
TA  - Journal of Neurology, Neurosurgery & Psychiatry
PG  - 448--450
VI  - 76
IP  - 3
4099  - http://jnnp.bmj.com/content/76/3/448.short
4100  - http://jnnp.bmj.com/content/76/3/448.full
SO  - J Neurol Neurosurg Psychiatry2005 Mar 01; 76
AB  - Efficacy and safety of long term use of FK506 (2–4.5 mg/day) for a maximum of two years were evaluated in 12 patients with generalised myasthenia gravis (MG). At the end of the study, eight patients (67%) showed improvement in either MG score or Activities in Daily Living score, and prednisolone dosage could be reduced in seven patients (58%), with a mean reduction ratio of 37%. Long term use of FK506 for MG can be more effective than short term administration, with no serious side effects.